Log in
NASDAQ:ATHA

Athira Pharma Stock Forecast, Price & News

$18.06
-0.82 (-4.34 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$18.06
Now: $18.06
$19.46
50-Day Range N/A
52-Week Range
$15.79
Now: $18.06
$22.14
Volume151,802 shs
Average Volume294,554 shs
Market Capitalization$556.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Athira Pharma Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHA
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$556.61 million
Next Earnings DateN/A
OptionableNot Optionable
$18.06
-0.82 (-4.34 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATHA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Athira Pharma (NASDAQ:ATHA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Athira Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Athira Pharma
.

What price target have analysts set for ATHA?

4 Wall Street analysts have issued 12-month target prices for Athira Pharma's stock. Their forecasts range from $30.00 to $53.00. On average, they anticipate Athira Pharma's share price to reach $42.50 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for Athira Pharma
.

Who are some of Athira Pharma's key competitors?

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), The Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

(ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Athira Pharma's stock symbol?

Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."

When did the company's quiet period expire?

Athira Pharma's quiet period expired on Wednesday, October 28th. Athira Pharma had issued 12,000,000 shares in its IPO on September 18th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Athira Pharma?

Shares of ATHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athira Pharma's stock price today?

One share of ATHA stock can currently be purchased for approximately $18.06.

How big of a company is Athira Pharma?

Athira Pharma has a market capitalization of $556.61 million.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.